D. E. Shaw & Co., Inc. Aurinia Pharmaceuticals Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 93,949 shares of AUPH stock, worth $748,773. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,949Holding current value
$748,773% of portfolio
0.0%Shares
27 transactions
Others Institutions Holding AUPH
# of Institutions
214Shares Held
58.3MCall Options Held
1.14MPut Options Held
1.51M-
Black Rock Inc. New York, NY9.27MShares$73.9 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY8.2MShares$65.4 Million1.0% of portfolio
-
Tang Capital Management LLC San Diego, CA7.23MShares$57.6 Million4.52% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$31.6 Million2.22% of portfolio
-
State Street Corp Boston, MA2.95MShares$23.5 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.13B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...